A new vaccine (Neuvax, nelipepimut-S or E75), which can prevent recurrence of early-stage, HER2 medium or low expression breast cancer, is being tested. Currently, since 2011 the vaccine is in a third phase of clinical trials but the preliminary results will be known in 2015. Vaccine is directed against E75 peptide isolated from the protein receptor HER2/neu. The results of the first and second phase of trials indicate reduced recurrence of the cancer than in the control group, lower mortality rate and the absence of bone metastasis in case of recurrence. In the article the way of action, patients’ criteria selection, results of the first and second phase of clinical trials, toxicity as well as perspective of spreading the vaccine, will be presented. Read full text »

In the UK alone, 500 000 people are infected with Hepatitis C virus (HCV) and still, most of the patients are not diagnosed. Therefore, HCV infection is a major cause of liver transplantation there. A few years ago, scientists have found monoclonal antibodies which gave hope for the acquisition of an effective vaccine. Now, the first results of the testing of vaccines based on adenoviral vectors have occurred. Read full text »